Clinical Breakthrough: Daraxonrasib Shows Significant Survival Benefit in Pancreatic Cancer Trial

The landscape of oncology is shifting as new data emerges for patients battling metastatic pancreatic ductal adenocarcinoma (PDAC), a condition historically defined by limited treatment options. On April 13, 2026, Revolution Medicines announced positive topline results from its global, randomized, Phase 3 RASolute 302 clinical trial, marking a potential turning point in the management of RAS-addicted cancers.

Understanding the RASolute 302 Results

The Phase 3 trial evaluated the efficacy of the oral therapy daraxonrasib in patients with metastatic PDAC who had already received prior treatment. The results demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS).

In the intent-to-treat study population, patients treated with daraxonrasib achieved a median overall survival of 13.2 months, compared to 6.7 months for those receiving standard-of-care intravenous cytotoxic chemotherapy. The trial reported a hazard ratio of 0.40, with a p-value of less than 0.0001, underscoring the strength of the clinical benefit observed.

According to the company, the therapy was generally well-tolerated, showing a manageable safety profile with no new safety signals identified during the study. Based on these interim findings, the trial’s primary and key secondary endpoints are considered final.

Strategic Next Steps for Revolution Medicines

Following these results, Revolution Medicines has outlined a clear regulatory path. The company intends to submit the data to global regulatory authorities, including the U.S. Food and Drug Administration (FDA). This submission is planned as part of a future New Drug Application, which the company intends to file under a Commissioner’s National Priority Voucher.

Beyond regulatory filings, the company plans to present the comprehensive findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, providing the medical community with a deeper look at the trial data.

Key Takeaways

• Clinical Efficacy: Daraxonrasib nearly doubled the median overall survival compared to standard chemotherapy in the study population (13.2 months vs. 6.7 months).
• Study Scope: The Phase 3 RASolute 302 trial was a global, randomized, controlled study focusing on patients with metastatic PDAC who had been previously treated.
• Safety Profile: The drug demonstrated a manageable safety profile with no new safety signals reported.
• Regulatory Path: Revolution Medicines is preparing to submit the data to the FDA and other global authorities, with an upcoming presentation scheduled for the 2026 ASCO Annual Meeting.

Looking Ahead

The results from the RASolute 302 trial represent a significant development for the oncology sector, particularly for the treatment of RAS-addicted cancers. As Revolution Medicines advances its regulatory strategy, the medical and investment communities will be closely watching for the formal presentation of these data. With the potential to offer a new standard of care for patients with advanced pancreatic cancer, daraxonrasib stands as a focal point in the current effort to address one of the most challenging areas of clinical oncology.

Disclaimer: This article is based on information provided by Revolution Medicines. Clinical trial results are subject to regulatory review and validation by health authorities.